Watertime, Author at PsyNews.com

Home Authors Posts by Watertime

429 POSTS 0 COMMENTS

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in...

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at...

Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

1...181920...43 Page 19 of 43

EDITOR PICKS

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in...

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at...

Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

EDITOR PICKS

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY